TRV734

TRV734 is a drug developed by Trevena, Inc. which acts as a biased agonist at the μ-opioid receptor, selective for activation of the G protein signaling pathway over β-arrestin 2 recruitment. It is closely related to oliceridine (TRV130) and has a similar pharmacological profile, but unlike oliceridine which has to be injected, TRV734 is suitable to be administered orally.^[2][3] The drug reached phase 2 clinical trials for treatment of pain but was discontinued for this indication.^[1][4] It is also under development for treatment of opioid-related disorders, in association with the National Institute on Drug Abuse (NIDA) and having reached phase 1 trials for this use, but no recent development has been reported.^[1][4]

Other namesTRV-734

Routes of
administrationOral^[1][2][3]

Drug classμ-Opioid receptor biased agonist; Analgesic

Elimination half-life1.9–2.5 hours^[3]

Quick facts Clinical data, Other names ...

TRV734

Clinical data
Other names	TRV-734
Routes of administration	Oral[1][2][3]
Drug class	μ-Opioid receptor biased agonist; Analgesic
Pharmacokinetic data
Elimination half-life	1.9–2.5 hours[3]
Identifiers
IUPAC name N-[(5-fluoropyridin-3-yl)methyl]-2-[(9R)-9-pyridin-2-yl-6-oxaspiro[4.5]decan-9-yl]ethanamine
CAS Number	1401029-50-2 Y
PubChem CID	72695064
Chemical and physical data
Formula	C22H28FN3O
Molar mass	369.484 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1CCC2(C1)C[C@](CCO2)(CCNCC3=CC(=CN=C3)F)C4=CC=CC=N4
InChI InChI=1S/C22H28FN3O/c23-19-13-18(15-25-16-19)14-24-11-8-21(20-5-1-4-10-26-20)9-12-27-22(17-21)6-2-3-7-22/h1,4-5,10,13,15-16,24H,2-3,6-9,11-12,14,17H2/t21-/m1/s1 Key:CRKVMJHROLSFMV-OAQYLSRUSA-N

Close